IMRA News and Press, IMARA Inc. From 05/11/21

On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the transfusion-dependent beta-thalassemia arm of the Forte Phase 2b trial Higher dose arms open...

BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company wil...

IMARA Inc. (NASDAQ:IMRA) traded at a new 52-week low today of $6.63. So far today approximately 219,000 shares have been exchanged, as compared to an average 30-day volume of 135,000 shares. In the past 52 weeks, shares of IMARA Inc. have traded between the current low of $6.63 and a hig...

IMARA Inc. (NASDAQ:IMRA) traded at a new 52-week low today of $6.95. Approximately 219,000 shares have changed hands today, as compared to an average 30-day volume of 136,000 shares. There is potential upside of 14.6% for shares of IMARA Inc. based on a current price of $7.01 and an aver...

IMARA Inc. (NASDAQ:IMRA) traded at a new 52-week low today of $7.49. This new low was reached on above average trading volume as 219,000 shares traded hands, while the average 30-day volume is approximately 132,000 shares. IMARA Inc. share prices have moved between a 52-week high of $62....

BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that applications ...

The following slide deck was published by IMARA Inc. in conjunction with this event. For further details see: IMARA (IMRA) Investor Presentation - Slideshow

Imara (IMRA) announces that separate independent data monitoring committees ((DMCs)) for the Ardent and Forte Phase 2b clinical trials of IMR-687 for sickle cell disease and beta-thalassemia have recommended opening of the higher dose IMR-687 treatment arm in each of these studies following r...

Independent Data Monitoring Committees endorse opening higher dose IMR-687 treatment arms in ongoing Ardent and Forte Phase 2b clinical trials after review of safety and tolerability data at lower doses Safety Review Committee in Phase 2a open label extension trial supports dail...

Imara, Inc. (IMRA) Q4 2020 Earnings Conference Call March 05, 2021, 08:30 ET Company Participants Michael Gray - CFO & COO Rahul Ballal - President, CEO & Director Conference Call Participants Matthew Harrison - Morgan Stanley Kelly Girskis - SVB Leerink Presentation Operator Ladies a...